Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
0.224
-0.014 (-5.68%)
At close: Apr 28, 2026, 4:00 PM EDT
0.226
+0.002 (1.03%)
After-hours: Apr 28, 2026, 4:39 PM EDT
Calidi Biotherapeutics Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Calidi Biotherapeutics.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Calidi Biotherapeutics.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $120 | Strong Buy | Initiates | $120 | +53,471.43% | Jun 27, 2024 |
| Baird | Baird | Buy Maintains $540 → $240 | Buy | Maintains | $540 → $240 | +107,042.86% | May 15, 2024 |
| Baird | Baird | Buy Maintains $1,080 → $540 | Buy | Maintains | $1,080 → $540 | +240,971.43% | Mar 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $1,320 → $240 | Strong Buy | Maintains | $1,320 → $240 | +107,042.86% | Mar 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $1,320 | Strong Buy | Initiates | $1,320 | +589,185.71% | Nov 22, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-5.68
from -5.95
EPS Next Year
-4.90
from -5.68
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -5.85 | -5.04 | |
| Avg | -5.68 | -4.90 | |
| Low | -5.46 | -4.70 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.